Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT596 with R-CHOP in B-Cell Lymphoma
NCT05934097Phase 1Withdrawn
- Sponsor
- Fate Therapeutics
- Start
- Dec 2022
- Primary completion
- May 2026
- Modality
- Gene Editing, Gene Silencing, Patient-derived iPSCs
01
Overview
Phase 1, open-label trial of FT596 in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more, sponsored by Fate Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities at Day 21 and Adverse Events up to 5 years. Planned start Dec 2022; status: withdrawn.
02
Drugs
FT596
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT05934097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934097.